In the case study presented here, spray drying was used to manufacture a dry-powder pulmonary formulation of bevacizumab, a monoclonal antibody approved to treat non-small-cell lung cancer (NSCLC) by intravenous infusion. By reformulating bevacizumab for local delivery, reduced side effects, lower doses, and improved patient compliance are possible. To learn more, please read our case study.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center